Eli Lilly and Company (NYSE:LLY) Shares Bought by Brookstone Capital Management

Brookstone Capital Management increased its position in Eli Lilly and Company (NYSE:LLY) by 6.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 33,029 shares of the company’s stock after acquiring an additional 2,089 shares during the period. Brookstone Capital Management’s holdings in Eli Lilly and Company were worth $29,262,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Reliant Investment Management LLC grew its position in Eli Lilly and Company by 4.4% in the 3rd quarter. Reliant Investment Management LLC now owns 1,387 shares of the company’s stock valued at $1,229,000 after buying an additional 59 shares in the last quarter. Artemis Investment Management LLP boosted its position in shares of Eli Lilly and Company by 29.9% during the 3rd quarter. Artemis Investment Management LLP now owns 55,474 shares of the company’s stock valued at $49,147,000 after purchasing an additional 12,769 shares in the last quarter. Country Trust Bank boosted its position in shares of Eli Lilly and Company by 1.6% during the 3rd quarter. Country Trust Bank now owns 95,627 shares of the company’s stock valued at $84,720,000 after purchasing an additional 1,500 shares in the last quarter. Atomi Financial Group Inc. boosted its position in shares of Eli Lilly and Company by 2.1% during the 3rd quarter. Atomi Financial Group Inc. now owns 5,394 shares of the company’s stock valued at $4,778,000 after purchasing an additional 111 shares in the last quarter. Finally, Legacy Private Trust Co. boosted its position in shares of Eli Lilly and Company by 5.7% during the 3rd quarter. Legacy Private Trust Co. now owns 8,712 shares of the company’s stock valued at $7,718,000 after purchasing an additional 471 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on LLY shares. Morgan Stanley restated an “overweight” rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $1,025.00 target price on shares of Eli Lilly and Company in a report on Thursday, October 3rd. Wells Fargo & Company raised their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Truist Financial reiterated a “buy” rating and issued a $1,000.00 target price (up from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Finally, Bank of America raised their target price on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $977.35.

Eli Lilly and Company Price Performance

Shares of LLY opened at $913.72 on Wednesday. The firm has a market cap of $868.40 billion, a PE ratio of 134.57, a PEG ratio of 2.78 and a beta of 0.42. The firm’s 50 day moving average price is $901.94 and its 200 day moving average price is $849.30. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. Eli Lilly and Company has a twelve month low of $547.61 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.64 by $1.28. The firm had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, research analysts expect that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.